Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients
Tumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations between the results of these assays and clinical outcomes, they are still not...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/57/6/636 |
| _version_ | 1797529520239017984 |
|---|---|
| author | Engin Ulukaya Didem Karakas Konstantinos Dimas |
| author_facet | Engin Ulukaya Didem Karakas Konstantinos Dimas |
| author_sort | Engin Ulukaya |
| collection | DOAJ |
| description | Tumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations between the results of these assays and clinical outcomes, they are still not considered routine tests in the care of cancer patients. The correlations between the assays’ results (drug sensitivity or resistance) and the clinical evaluations (e.g., response to treatment, progression-free survival) are highly promising. However, there is still a need to design randomized controlled prospective studies to secure the place of these assays in routine use. One of the best ideas to increase the value of these assays could be the combination of the assay results with the omics technologies (e.g., pharmacogenetics that gives an idea of the possible side effects of the drugs). In the near future, the importance of personalized chemotherapy is expected to dictate the use of these omics technologies. The omics relies on the macromolecules (Deoxyribonucleic acid -DNA-, ribonucleic acid -RNA-) and proteins (meaning the structure) while TCAs operate on living cell populations (meaning the function). Therefore, wise combinations of TCAs and omics could be a highly promising novel landscape in the modern care of cancer patients. |
| first_indexed | 2024-03-10T10:15:55Z |
| format | Article |
| id | doaj.art-c29812a0d3e24aa4bfaaa816c7733b3a |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T10:15:55Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-c29812a0d3e24aa4bfaaa816c7733b3a2023-11-22T00:52:14ZengMDPI AGMedicina1010-660X1648-91442021-06-0157663610.3390/medicina57060636Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer PatientsEngin Ulukaya0Didem Karakas1Konstantinos Dimas2Department of Clinical Biochemistry, Faculty of Medicine, Istinye University, Istanbul 34010, TurkeyDepartment of Molecular Biology and Genetics, Faculty of Science and Letters, Istinye University, Istanbul 34010, TurkeyDepartment of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, GreeceTumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations between the results of these assays and clinical outcomes, they are still not considered routine tests in the care of cancer patients. The correlations between the assays’ results (drug sensitivity or resistance) and the clinical evaluations (e.g., response to treatment, progression-free survival) are highly promising. However, there is still a need to design randomized controlled prospective studies to secure the place of these assays in routine use. One of the best ideas to increase the value of these assays could be the combination of the assay results with the omics technologies (e.g., pharmacogenetics that gives an idea of the possible side effects of the drugs). In the near future, the importance of personalized chemotherapy is expected to dictate the use of these omics technologies. The omics relies on the macromolecules (Deoxyribonucleic acid -DNA-, ribonucleic acid -RNA-) and proteins (meaning the structure) while TCAs operate on living cell populations (meaning the function). Therefore, wise combinations of TCAs and omics could be a highly promising novel landscape in the modern care of cancer patients.https://www.mdpi.com/1648-9144/57/6/636tumor chemosensitivity assaydrug response assaytreatmentpharmacogenetics |
| spellingShingle | Engin Ulukaya Didem Karakas Konstantinos Dimas Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients Medicina tumor chemosensitivity assay drug response assay treatment pharmacogenetics |
| title | Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients |
| title_full | Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients |
| title_fullStr | Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients |
| title_full_unstemmed | Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients |
| title_short | Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients |
| title_sort | tumor chemosensitivity assays are helpful for personalized cytotoxic treatments in cancer patients |
| topic | tumor chemosensitivity assay drug response assay treatment pharmacogenetics |
| url | https://www.mdpi.com/1648-9144/57/6/636 |
| work_keys_str_mv | AT enginulukaya tumorchemosensitivityassaysarehelpfulforpersonalizedcytotoxictreatmentsincancerpatients AT didemkarakas tumorchemosensitivityassaysarehelpfulforpersonalizedcytotoxictreatmentsincancerpatients AT konstantinosdimas tumorchemosensitivityassaysarehelpfulforpersonalizedcytotoxictreatmentsincancerpatients |